The Latest Cardiac and Vascular News
CAMBRIDGE, England, June 29, 2023 /PRNewswire/ — PocDoc, the Cambridge-based digital health platform, today announces a major pilot with the NHS Targeted Lung Health Check programme in the North East, in partnership with cardiologist Dr Alan Bagnall and the NIHR Clinical Research Network North East and North Cumbria (CRN NENC). As documented widely in recent weeks, the NHS England Targeted […]
SEOUL, Korea, June 28, 2023 (GLOBE NEWSWIRE) — Kalos Medical Inc. (“Kalos Medical”), a developer of innovative medical devices treating hypertension and other chronic illnesses, announced on June 23rd that South Korea’s Ministry of Food and Drug Safety (“MFDS”) designated the company’s DENEX hypertension treatment system as an Innovative Medical […]
Global clinical study aims to broaden evidence base by assessing clinical and economic benefits for the FFRangio System First patient enrolled at Ascension St. John Hospital in Michigan KFAR-SABA, Israel and IRVINE, Calif., June 28, 2023 /PRNewswire/ — CathWorks announced today that the first patient has been enrolled in the Advancing Cath Lab Results with FFRangio Coronary Physiology […]
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the application was filed for a Type II(a) variation with the European Medicines Agency (EMA) […]
Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million upfront payment from finance agreement with HealthCare Royalty Pharmosa to receive up to $215 million in development and sales milestones for PAH and PH-ILD indications, […]
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 […]
ATCOR and Datacubed Health partner on a novel remote trial solution to integratedigital vascular biomarker patient monitoring within the Datacubed Health PatientEngagement Platform IRVINE, Calif., June 26, 2023 /PRNewswire/ — ATCOR Medical, subsidiary of CardieX and developer of innovative medical devices and digital solutions to personalize healthcare and improve clinical trial patient outcomes, today announces it […]
First-of-its-Kind Data Underscore Importance of Early Use of Drug Therapy as a Primary Prevention, Especially for Those Living with Diabetes SAN DIEGO, June 24, 2023 /PRNewswire/ — Today, a new trial revealed data on the effects of bempedoic acid – a non-statin cholesterol-lowering drug – on cardiovascular outcomes, demonstrating that patients with […]
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and tolerability profile – – SHTG Phase 3 ENTRUST trial initiated in May 2023 – SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company […]
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian markets, today announced that CAMZYOS® (mavacamten) has received marketing approval for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from the […]
